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Thedetection ofbreast carcinoma cells ineﬀusionsisassociatedwithrapidlyfataloutcome,butthesecells arepoorlycharacterized
at the molecular level. This study compared the gene array signatures of breast carcinoma cells in primary carcinomas and
eﬀusions. The genetic signature of 10 primary tumors and 10 eﬀusions was analyzed using the Array-Ready Oligo set for the
Human Genome platform. Results for selected genes were validated using PCR, Western blotting, and immunohistochemistry.
Array analysis identiﬁed 255 signiﬁcantly downregulated and 96 upregulated genes in the eﬀusion samples. The majority of
diﬀerentially expressed genes were part of pathways involved in focal adhesion, extracellular matrix-cell interaction, and the
regulation of the actin cytoskeleton. Genes that were upregulated in eﬀusions included KRT8, BCAR1, CLDN4, VIL2, while
DCN, CLDN19, ITGA7,a n dITGA5 were downregulated at this anatomic site. PCR, Western blotting, and immunohistochemistry
conﬁrmed the array ﬁndings for BCAR1, CLDN4, VIL2,a n dDCN. Our data show that breast carcinoma cells in primary
carcinomas and eﬀusions have diﬀerent gene expression signatures, and diﬀerentially express a large number of molecules related
to adhesion, motility, and metastasis. These diﬀerences may have a critical role in designing therapy and in prognostication for
patients with metastatic disease localized to the serosal cavities.
1.Introduction
Breast cancer is the most common malignancy in women,
constituting more than 25% of cancers in this group. The
incidence of breast cancer around the world greatly varies,
with highest rates in the North America, Western, and
Northern Europe and Australia/New Zealand (82.5–99.4 per
100,000women).Mortalityintheseareasofhighincidenceis
19.2–22.6 per 100,000 women [1]. Breast cancer metastasizes
most often to axillary lymph nodes, but may involve any
organ. Metastasis to serosal surfaces involves primarily the
pleural cavity [2, 3], and infrequently, the pericardial and
peritoneal cavities [4]. Pleural eﬀusions may occur at any
point of time in the clinical course and may be the sole
manifestation of metastatic disease [5]. This condition is
associated with a poor median survival of less than 1 year
[5, 6].
In recent years, we have reported on the diﬀerential
expression of metastasis-related molecules, including pro-
teases, angiogenic molecules, signaling molecules, inhibitors
of apoptosis, and transcription factors, in breast carcinoma
eﬀusions compared to patient-matched primary carcinomas
[7–10]. However, these studies focused on a limited number
of genes. The global view of cellular transcriptional activity2 Journal of Oncology
using gene array technology is required to identify clusters of
geneticmarkersthatexplainthecomplexbiologicalprocesses
involved in carcinoma progression to eﬀusions. At present,
only one study in which breast carcinoma eﬀusions were
compared with primary carcinomas is available. Dupont et
al. analyzed the gene expression signature of 19 eﬀusions and
compared them to 4 primary carcinomas, 8 cells lines and 4
specimens consisting of benign breast tissue. Eﬀusions could
be diﬀerentiated into two categories, one resembling cells
lines and expressing CD24, CD44 and cytokeratins 8, 18 and
19, the other expressing metastasis-associated genes, such as
S100A4, uPA receptor, vimentin and CXCR4 [11].
The present study compared the gene expression sig-
natures of 10 eﬀusions and 10 primary breast carcinomas.
Selected diﬀerentially expressed genes of pathways related to
adhesion, interaction with the extracellular matrix (ECM)
and regulation of the actin cytoskeleton were validated on
mRNA and protein level, and their clinical relevance was
analyzed in a larger series of breast carcinoma eﬀusions. Our
datademonstratethatinagreementwithourpreviousobser-
vations, breast carcinoma cells in eﬀusions are markedly
diﬀerent from their counterparts in primary carcinomas.
Thisbearsrelevancetovalidationofnoveltherapeutictargets
and stratiﬁcation of patients with respect to treatment
response and survival.
2.MaterialsandMethods
2.1. Patients and Material
2.1.1. Eﬀusions. Ten eﬀusions (7 pleural, 2 peritoneal, 1
pericardial) from patients with primary breast carcinoma
(9 of inﬁltrating ductal type, 1 lobular) were submitted for
routine diagnostic purposes to the Department of Pathology
at the Norwegian Radium Hospital during the period 1999–
2005. Submitted specimens were processed immediately
upon arrival, and pellets were used for preparation of
paraﬃn-embedded cell blocks and for freezing in equal
volumes of RPMI supplemented with 20% fetal calf serum
and 20% DMSO. All specimens underwent morphological
evaluation and were further characterized using immuno-
histochemistry, as previously detailed [12]. All eﬀusions had
>50% carcinoma cells of the total cellular content, ranging
between 80–100% of cells in 8/10 specimens. Study approval
was given by the Regional Committee for Medical Research
Ethics in Norway.
2.1.2. Primary Tumors. Ten primary breast carcinomas
of inﬁltrating duct type were retrieved from snap-frozen
archival material stored at −70◦C at the Department of
Pathology, Norwegian Radium Hospital. Morphological
evaluation of frozen sections from the studied specimens
was performed in all cases in order to ensure the presence
of a predominant carcinoma cell population and absence of
necrosis.
2.2. Gene Array. Eleven samples were prepared from each
group (one eﬀusion and one primary carcinoma with two
samples each). Analysis of diﬀerentially expressed genes
was performed by two experimental designs. (1) Eleven
pair-wise competitive hybridizations of cDNA target sample
from randomly chosen patients from the eﬀusion group
and sample from randomly chosen patients from primary
solid tumor group. (2) Six pair-wise hybridizations of cDNA
samples from randomly chosen patients from the eﬀusion
group and pooled reference sample from four primary solid
tumors.
2.2.1. RNA Extraction. Biopsies from primary tumors and
eﬀusions were lysed using SV- total isolation kit (Promega,
Madison, Wis, USA) and total RNA was extracted according
to the manufacturer’s guidelines. The quantity and quality of
the total RNA preparations were assessed using a NanoDrop
ND-1000 (NanoDrop, Wilmington, De, USA) combined
with agarose gel electrophoresis and only samples with
ribosomal 28S/18S ratio near 2 were selected for array
analysis.
2.2.2. Reverse-Transcription Reaction. Twenty micrograms
total RNA was mixed with 2μg oligo dT (Amersham
Biosciences, Piscataway, NJ, USA) and RNAse-free water to
a total volume of 16.9μL, incubated 10 minutes at 75◦Ca n d
cooled on ice. Six microliters of ﬁrst strand buﬀer, 3μLo f
0.1M DTT, 2μL of Superscript II RT (Invitrogen, Carlsbad,
Calif, USA), 1.2μL 25X Aminoallyl (aa-aUTP)/d-NTP mix
(Sigma, Haverhill, UK) and 1μL of RNAse inhibitor (Amer-
sham Biosciences) were added to each reaction tube. The
mixture was centrifuged brieﬂy and incubated 60 minutes
at 42◦C. Additional 1μLo fS u p e r s c r i p tI IR Tw a sa d d e d
following incubation for 60 minutes at 42◦C.
2.2.3. RNA Hydrolysis. Free RNA was disassembled with
mixture of 10μL 1M NaOH and 10μL0 . 5 ME D T Aa n d
underwent neutralization with 25μL1MH e p e s .
2.2.4. cDNA Puriﬁcation. Unincorporated aa-aUTP and free
amines were removed using Microcon YM-30 spin column
(Millipore, Bedford, Mass, USA) and cDNA yield were
measured by Nanodrop spectrophotometer. The sample was
dried at RT using speed-vac.
2.2.5. Coupling Cyanine Dye Ester to aa-cDNA. The cDNA
target samples were labeled by Cy3 or Cy5 ﬂuorescent dyes
(Amersham Biosciences) according to the sample group
and resuspended in 0.1M Carbonate buﬀer (pH 8.6). The
samples were incubated in the dark for 1 hour in RT and
dilutedin35μLNaOAc100mM(pH5.2).Thefreedyeswere
removed using QIAquik PCR clean up kit (Qiagen, Valencia,
CA, USA), washed with 5mM phosphate buﬀer (pH 8.0,
80% ethanol) and eluted with 4mM Phosphate elution
buﬀer (pH 8.5). The hybridization eﬃciency and the yield of
the dye incorporation were calculated using Labeled cDNA
Calculator (http://www.pangloss.com/seidel/Protocols/
percent inc.html). Equal amount of Cy3/Cy5 labeled cDNA
were mixed and dried in the speed-vac.Journal of Oncology 3
2.2.6. Hybridization. The slides, with printed Array-Ready
Oligo set for the Human Genome Version 3.0 (Qiagen)
containing34,580longmerprobes,representing24,650genes
and 37,123 gene transcripts, were blocked with 1%BSA in
0.1% SDS 5XSSC buﬀer, washed in distilled water and dried
at 1000rpm for 2 minutes. The mixed pair of samples was
resuspended in hybridization buﬀer (25% Formamide, 0.1%
SDS in 5XSSC) supplied with 0.02μg t-RNA and denatured
at 95◦C. The arrays were hybridized in a water bath, in
sealed, watertight hybridization chambers (DieTech, Ford
City, Pa, USA) for 16–18 hours at 42◦C. After hybridization,
the slides were rinsed in a coupling jar containing 2 ×
SSC 0.1% SDS, followed by washing for 5 minutes in
1 × SSC, then for 5 minutes in 0.2 × SSC, and ﬁnally
for 10 minutes in 0.05 × SSC. The slides were dried as
described above. The ﬁnal visualization is carried out using
Axon 4000B ﬂuorescence scanner. Griding and analysis of
images was performed using Gene Pix 6.0 software package
(Molecular Devices, Sunnyvale, Calif, USA). Speciﬁc genes
were characterized according to ﬂuorescence intensity of
Cy3/Cy5 Dyes. The ﬂuorescent intensities of Cy5 and Cy3
for each target spot were adjusted so that the mean Cy3/Cy5
ratio of housekeeping genes was equal to one, a design
allowing more precise analysis of diﬀerentially expressed
genes.
2.2.7. Statistics. Statistical analysis of microarrays was pre-
formed by The Genomic Data Analysis Unit of Hadassah
Medical School, Hebrew University of Jerusalem.
The quality assurance, calibration, data normalization
(Lowess)[13]andVolcanoplotforGPRﬁleswereperformed
by custom built package written in MATLAB R2007a. An
additional statistical analysis and clustering were carried out
using the Spotﬁre (Somerville, MA) and Partek (St. Louis,
MO) software packages.
Gene annotations and speciﬁc pathways were ﬁn-
gered out using online free access programs such as: GO
annotation (http://www.geneontology.org/), Onto-Express,
Pathway-Express (Intelligent Systems and Bioinformatics
Laboratory, Computer Science Department, Wayne State
University).
2.3. Reverse Transcription Polymerase
C h a i nR e a c t i o n( R T - P C R )
2.3.1. Reverse-Transcriptase Reaction. Total RNA from spec-
imens analyzed for BCAR1,VIL2 and DCN expression
was extracted using Tri-Reagent (Sigma) according to
the manufacturer’s guidelines. 0.5μg total RNA was
reverse-transcribed using the M-MLV Reverse Transcriptase
(Promega) with incubation of 2 hours at 37◦C, followed by 5
minutes at 95◦C, and diluted to 1 : 5 with RNase-free water.
2.3.2. Semiquantitative RT-PCR. RT-PCR was performed on
complementary DNA samples using a DNA thermal cycler
(Eppendorf Mastercycler gradient, Eppendorf, Hamburg,
Germany) with Reddymix PCR master mix (ABgene, Surrey,
UK). Primer sequence was as follows:
BCAR1. sense 5 -GGG-CCA-CAG-GAC-ATC-TAT--
GAT-3 , antisense 5 -GAG-GAA-CGT-CGT-AGA-CTG-
CG-3  (amplicon size, 318 base pairs [bp]). VIL2. sense 5 -
GTT-TTC-CCC-AGT-TGT-AAT-AGT-GCC-3 , antisense
5 -TGC-CTT-TGC-AAA-GCT-TTT-ATT-TCA-3  (ampli-
con size, 995 bp).
Conditions were as follows: BCAR1:9 5 ◦Cf o r3m i n u t e s ,
denaturation at 95◦ for 15 seconds, annealing at 59◦ for 30
seconds, extension at 72◦ for 20 seconds, 34 cycles; VIL2:9 5 ◦
for 3 minutes, denaturation at 95◦ for 15 seconds, annealing
at 64◦ for 30 seconds, extension at 72◦ for 20 seconds,
33 cycles. The HT-1080 ﬁbrosarcoma cell line served as a
positive control in both reactions.
Products were separated on 1.5% agarose gels, isolated
using the Invisorb Spin DNA extraction kit (Invitek GmbH,
Berlin, Germany) and sequenced. Gels were photographed
by the Kodak EDAS 290 system (Kodak, Rochester, NY,
USA). Densitometer analysis of ﬁlms was performed using a
computerized image analysis (NIH IMAGE 1.63) program.
BCAR1 and VIL2 mRNA levels were established by calcu-
lating the target molecule/28S ratio (all cases scored for
band intensity compared to control). Expression intensity
of 5% or less of control levels was interpreted as nega-
tive. Measurements were made at the linear phase of the
reaction.
2.3.3. Quantitative RT-PCR (qRT-PCR). qRT-PCR was pre-
formed using the Mx3000P QPCR System (Stratagene,
Calif, USA). Oligonucleotide primers were designed in the
Primer Express program (Applied Biosystems, Foster City,
Calif, USA). Primer sequences for DCN were 5 -TCC-GCT-
GAA-GAG-CTC-AGG-AAT-3  for the forward primer, and
5 -CCT-TGA-GGA-ATG-CTG-GTG-ATA-TTG-3  for the
reverse primer. The primers for RPLPO normalizer gene
were: 5 -CCA-ACT-ACT-TCC-TTA-AGA-TCA-TCC-AAC-
TA-3  for the forward primer and 5 -ACA-TGC-GGA-TCT-
GCT-GCA-3  for the reverse primer. One of the primers
in each primer pair was designed in exon-exon boundaries
region in order to minimize the DNA contamination noise.
The speciﬁcity of primer binding was analyzed by BLAST
(http://blast.ncbi.nlm.nih.gov/) with Human genomic +
transcript (Human G + T) database for highly similar
sequences (megablast). The primer optimal concentration
and the sensitivity, eﬃciency, and accuracy of qPCR were
calibrated by amplifying serial geometric dilutions of pooled
sample consisted from ﬁve primary tumor and ﬁve eﬀusion
cDNA samples. 0.1μg of cDNA product from the Reverse
Transcriptase reaction were ampliﬁed using DyNAmo SYBR
Green qPCR Kit with ROX passive reference dye (Finnzymes
Oy,Espoo,Finland)accordingtothemanufacturer’sinstruc-
tions. Absence of primer-dimers and non-speciﬁc products
was veriﬁed by single product peak in the qPCR dissoci-
ation curve. In addition, the PCR product was separated
by gel electrophoresis and sequenced (Hebrew University
facilities).
2.4. Immunohistochemistry. Formalin-ﬁxed paraﬃn-embed-
ded sections were available from 52 breast carcinoma4 Journal of Oncology
eﬀusions (47 pleural, 4 peritoneal, 1 pericardial) from 51
female patients (one patient with 2 eﬀusions) aged 33–86
(mean = 59) years with histologically veriﬁed breast cancer.
In 27 cases, the primary carcinoma was additionally available
for analysis.
Slides from the primary breast carcinoma specimens
were available in our archives for 45 cases. These were
diagnosed as inﬁltrating duct carcinoma (38), lobular car-
cinoma (5) or mixed duct and lobular carcinoma (2). In the
remaining 6 cases, eﬀusion specimens were submitted to our
clinic from patients operated at other hospitals.
These 79 above-described specimens were manually
immunostained for p130cas, phospho-Ezrin (p-Ezrin), and
claudin-4. The monoclonal mouse p130cas antibody (clone
CAS-14) was purchased from NeoMarkers (LabVision Cor-
poration, Fremont, Calif, USA). A monoclonal mouse p-
Ezrin antibody was purchased from BD Pharmingen (San
Jose, Calif, USA). The rabbit polyclonal claudin-4 antibody
was purchased from Zymed (San Francisco, Calif, USA). All
slides underwent pretreatment in a microwave oven for 20
minutes (p-Ezrin and claudin-4 slides in Tris/EDTA buﬀer,
pH = 9-9.1, p130cas slides in citrate buﬀer, pH = 6). Antibody
dilutions were 1 : 200 for all antibodies. Visualization was
achieved using the EnVision + peroxidase system (Dako A/S,
Glostrup, Denmark).
Negative controls consisted of sections that under-
went similar staining procedures with isotype-matched
mouse antibody, normal goat IgG or non-relevant rabbit
immunoglobulins according to the antibody host species.
Positive controls consisted of a breast carcinoma biopsy that
demonstrated immunoreactivity for the studied antigens in
a pilot study.
Staining was considered positive only when localized
to the cell membrane in a linear pattern for p-Ezrin and
claudin-4,andwhenpresentinthecytoplasmforthep130cas
reaction. Staining extent was scored on a scale of 0–4, as
follows: 0 = no staining, 1 = staining of 1–5%, 2 = staining of
6–25%, 3 = staining of 26–75%, 4 = staining of 76–100% of
cells.Nospecimencontainedlessthan100tumorcells.Slides
were scored by a surgical pathologist experienced in eﬀusion
cytology and breast pathology (BD).
2.5. Western Blotting. Frozen specimens were thawed and
subsequently lysed in 1% NP-40, 20mM Tris HCl (pH
7.5), 137mM NaCl, 0.5mM EDTA, 10% glycerol, 1mM
phenyl-methylsulfonyl ﬂuoride, 1μg/mL Aprotinin, 2μg/mL
leupeptin, 1mM sodium orthovanadate, and 0.1% SDS.
25μg of a total protein from each sample were separated by
electrophoresisthroughSDS-10%polyacrylamidegelsunder
reducing conditions. After electrophoresis, proteins were
transferred to Immobilon transfer membranes (Millipore,
Bedford, Mass, USA). Membranes were blocked in 5% Non
Fat Dry Milk (NFDM) in 0.1% Tween TBS (TBST) and
incubatedovernightat4◦Cin5%BSATBSTcontaininganti-
p-Ezrin(Thr567)rabbitmAb(CellSignalingTechnologyInc.,
Danvers, Mass, USA).
After incubation, membranes were washed and incu-
b a t e df o r1h o u rw i t hp e r o x i d a s e - c o n j u g a t e dA ﬃniPure goat
anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA,
USA) in TBST containing 5% BSA. Membranes were devel-
oped using the enhanced chemiluminescence kit (Pierce,
Rockford, Ill, USA), according to manufacturer’s speciﬁ-
cations. Membranes were then washed, stripped in 0.2M
glycine, 0.1% SDS, and 1% Tween 20 (pH 2.2), blocked in
TBST containing 5% NFDM, and incubated overnight at
4◦C in 5% BSA in TBST containing a rabbit polyclonal anti-
Ezrin Ab (Abcam, Cambridge, UK). Total Ezrin activity was
normalized to β-actin activity measured using rabbit anti-β-
actin polyclonal antibody (Cell Signaling Technology Inc.).
Protein detection was preformed as described above. Protein
lysate from MCF-7 breast carcinoma cells served as control.
Levelsofphosphrylation oftheTORC1substratep70S6K
were analyzed using goat anti-p-p70S6KThr389 and rabbit
anti-p70 S6K antibodies (Santa Cruz biotechnology, inc.,
Santa Cruz, Calif, USA) as described above. Secondary
peroxidase-conjugated donkey anti-goat IgG (Santa Cruz
biotechnology, inc.) was used for anti-p-p70S6KThr389 detec-
tion.
2.5.1.QuantiﬁcationofBlottingResults. Gelswerescannedby
theKODAKEDAS290system.Densitometeranalysisofﬁlms
wasperformedusingacomputerizedimageanalysisprogram
(NIH IMAGE 1.63)
3.StatisticalAnalysis
IHC and IB results were analyzed using the SPSS-PC
package, version 15.0 (Chicago, Ill, USA). Comparative
analyses of tumor cell expression results in all eﬀusions
versus primary tumors were performed using the Mann-
Whitney U test. The same test was applied for analysis of
the relationship between protein expression in eﬀusions and
clinicopathologic parameters. The Wilcoxon Signed Ranks
test was applied for patient-matched analysis in the 27 cases
with eﬀusion and primary tumor. Univariate analysis for
disease-free survival (DFS) and overall survival (OS) for 44
patients with clinical data were executed using the Kaplan-
MeiermethodandLog-ranktest.Forthisanalysis,expression
categories were grouped as focal (≤25% of cells) or diﬀuse
(>25% of cells).
4. Results
4.1. Breast Carcinoma Eﬀusions and Primary Carcinomas
Have Diﬀerent Gene Expression Patterns. We have previously
shown that eﬀusions constitute a unique form of breast
carcinoma metastasis with mRNA and protein expression
patterns that diﬀer from primary tumors and solid metas-
tases [7–10]. In the present study, we compared the global
expression proﬁle of breast carcinoma cells in eﬀusions with
that of primary carcinomas.
Figure 1(a) shows volcano plot of global gene expression
in eﬀusions and primary tumors. Diﬀerences of 1–5 fold in
gene expression with cut-oﬀ P-value <.05 were deﬁned as
signiﬁcant. We identiﬁed 255 signiﬁcantly down-regulatedJournal of Oncology 5
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Figure 1: Breast carcinoma eﬀusion and primary carcinoma expression arrays. (a): Volcano plot of diﬀerentially expressed genes in malignant
eﬀusions in comparison to pooled primary tumors (n = 6). The x-axis indicates the diﬀerential expression proﬁles, plotting the fold-
induction ratios in a log-2 scale. The y-axis indicates the statistical signiﬁcance of the diﬀerence in expression (P-value, t-test) in a -log10
scale. Diﬀerentially expressed genes (P<. 05) appear above the horizontal line. Numbers denote up-regulated (red) or down-regulated
(blue) genes in eﬀusions. (b): Gene expression proﬁling of eﬀusions (blue) and primary breast carcinomas (red) in three-dimensional space
by Principal Component Analysis using 351 genes that showed signiﬁcant up- or downregulation in eﬀusions in comparison to the pooled
primary tumor sample (two diﬀerent view angles). (c): Gene expression proﬁling of 11 eﬀusions (blue) and 11 primary carcinomas (red) in
three-dimensional space by Principal Component Analysis (three diﬀerent view angles).
and 96 signiﬁcantly up-regulated genes in eﬀusion samples
(total = 351).
4.1.1. PCA Analysis. Principal Component Analysis (PCA)
(Partek, St. Louis, Mon, USA) is a technique used to reduce
multidimensional data sets to lower dimensions and to
highlight their similarities and diﬀerences. PCA analysis of
six eﬀusion and primary tumor samples was performed
using the set of 351 genes that were diﬀerentially expressed
in eﬀusions and primary carcinomas (Figure 1(b),s u p -
plementary Table 1, available at doi:10.1155/2010/969084.).
Selected genes are shown in Table 1. The analysis showed
that this gene set eﬀectively separates tumors at these two
anatomic sites. We additionally performed random PCA
analysis of the gene expression pattern in all 11 eﬀusions6 Journal of Oncology
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Figure 2: Dendrogram. A dendrogram of a supervised analysis of
386 genes (horizontal rows) across 6 eﬀusion versus six primary
tumor replicates. Each cell in the matrix represents the expression
level of a single transcript in a single sample. The supervised hier-
archical clustering analysis clearly distinguished between eﬀusion
and control expression pattern. Red or green color indicates high
or low transcript levels relative to threshold based on overall gene
expression values across each array slide, respectively, while black
color indicates equal to median level of expression.
and 11 primary tumor pairs (Figure 1(c)). The analysis was
performed using a set of 342 genes that showed trend of up-
or downregulation in those patients. The diﬀerence between
this gene number and the above-detailed 351 genes results
from the fact that two diﬀerent analyses were performed, the
ﬁrst being a pool versus individual specimen analysis, the
second of individual case versus individual case. However,
the pathways detected were identical. Three patterns were
identiﬁed: (1) unique for primary tumors; (2) unique for
eﬀusions and (3) samples with overlapping gene expression.
4.2. Gene Ontology and Function. I no r d e rt ou n d e r s t a n d
the biological function of the genes that were up- or
down-regulated in eﬀusions, we used the GO annotation
(http://www.geneontology.org/) and Pathway-Express (14,
15) programs.
We found multiple pathways involved in cell mainte-
nance that are altered in eﬀusions in comparison to primary
tumors (Table 2). It can be seen that the pathways involved
in focal adhesion, ECM-receptor interaction and regulation
of the actin cytoskeleton are highly involved in phenotypic
transformation of carcinoma cells in primary tumors to
those in eﬀusions. Some of the diﬀerentially-expressed genes
were found to participate in the speciﬁc pathways listed
above. Other diﬀerentially-expressed genes could not be
classiﬁed as components of a speciﬁc pathway, but are of
great clinical impact in breast carcinoma, for example, ERβ
with a 3.23-fold downregulation in eﬀusions and MTA3, an
estrogen-sensitive gene involved in E-cadherin regulation,
with a 2.42- fold downregulation in eﬀusions.
4.3. Hierarchical Clustering of Gene Expression Proﬁles. The
signiﬁcantly altered genes in eﬀusions (t-test/ ANOVA, P-
value <.05) were selected for performing UPGMA hier-
archical clustering (Figure 2). The unsupervised clustering
analysis was performed using the Spotﬁre software. The
diﬀerentially expressed genes were classiﬁed into 10 major
clusters. Of these 10 clusters, cluster G included genes that
were strongly up-regulated in eﬀusions, while cluster J genes
were strongly down-regulated in comparison to primary
tumors. We found some clinically-relevant genes, such as
KRT8, CLDN4 and VIL2 in cluster G, while cluster J included
CLDN19, the ECM genes COL1A1, COL22A1, COL5A2 and
the ITGA7 and ITGA5 integrin genes.
4.4. Validation of Gene Array Results. Since cell motility
and cell-ECM interactions may have a major eﬀect on
the metastatic potential of carcinoma cells in eﬀusions, we
focused on genes participating in regulation of the actin
cytoskeleton, focal adhesion, and ECM-receptor interactions
in validation of the array results. The genes focused on were
the following: DCN, which encodes for the small cellular
or pericellular matrix proteoglycan decorin [14]a n dw a s
found to be signiﬁcantly down-regulated in eﬀusions; VIL2,
encoding for ezrin, which controls the actin cytoskeleton
dynamics; BCAR,encodingfortheintegrinsignalingadaptor
protein p130cas. In addition, Tuberous Sclerosis 1 (TSC1),
also known as the tumor suppressor hamartin, the main
inhibitor of the mTOR signaling pathway [15, 16], was
one of the genes that were found to be down-regulated
in eﬀusions in comparison to primary tumors. Thus, we
decided to analyze mTOR activity in eﬀusions compared to
solid primary tumors. Validation was by semiquantitative
andquantitativeRT-PCR,WesternBlottingandimmunohis-
tochemistry, using an enlarged set of eﬀusions and primary
carcinomas.
4.4.1. DCN. DCN expression levels were analyzed in 29
eﬀusions and 35 primary carcinomas using qRT-PCR. DCN
levels were signiﬁcantly higher in primary tumors (P<
.0001, Figure 3(a)), in agreement with the gene array results.
4.4.2.BCAR1/p130cas. SemiquantitativeRT-PCRanalysisof
35 primary tumors and of 29 eﬀusions showed signiﬁcantly
higher up-regulation of BCAR1 in eﬀusions (P<. 0001,
Figure 3(b)). Immunostaining of 52 eﬀusions and 26 of
the 27 primary carcinomas (one unsatisfactory reaction)
for p130cas showed its presence in tumor cells in 50/52Journal of Oncology 7
Table 1: Selected genes identiﬁed by fold-change analysis using the MATLAB R2007a program that are diﬀerentially expressed in primary
tumors versus eﬀusions (complete list available in supplementary Table 1).
Genes more highly expressed in eﬀusions
Gene Full name Log2 change
CLDN4 Claudin-4 4.8544
KRT8 Keratin 8 3.9099
NTN4 Netrin-4 3.5957
VIL2 Villin 2 2.7965
FASN Fatty acid synthase 2.7583
DLX3 Distal-less homeobox 3 2.3846
ZNF75C ZNF75C 2.2346
TRAF4 TNF-receptor-associated factor 4 2.0682
NEDD4L Neural precursor cell expressed, developmentally down-regulated 2.0061
NPC1L1 NPC1 (Niemann-Pick disease, type C1 gene)-like 1 1.9928
Genes more highly expressed in primary tumors
CLDN19 Claudin-19 20.4327
HPR Haptoglobin-related protein 11.7846
IGFBP7 Insulin-like growth factor binding protein 7 10.6376
ZFYVE20 Zinc ﬁnger FYVE domain containing 20 10.4542
HP Haptoglobin 9.1384
GFRA1 GDNF family receptor alpha 1 8.6866
APOBEC2 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2 8.6565
STK39 Serine threonine kinase 39 (STE20/SPS1 homolog, yeast) 8.0239
SLC6A16 Solute carrier family 6, member 16 7.2568
eﬀusions and 24/26 primary carcinomas (Figures 4(a) and
4(b)). Comparative analysis showed no signiﬁcant diﬀerence
in staining extent at these two anatomic sites (P>. 05).
OS for the 44 patients with survival data ranged from 2–
393 months (mean = 90 months), while DFS ranged from 0–
336 months (mean = 55 months). In survival analysis, higher
p130cas expression in eﬀusions was associated with a trend
for poor OS (P = .062) and DFS (P = .098; Figure 5).
4.4.3. VIL2/Ezrin. Semiquantitative RT-PCR analysis of 43
primary tumors and 25 eﬀusions showed signiﬁcantly higher
VIL2 expression in eﬀusions (P = .0021, Figure 3(c)).
Protein levels and phosphorylation extent of Ezrin were
analyzed by Western blotting using phospho- and pan-
speciﬁc antibodies. Pan-Ezrin protein level was signiﬁcantly
higher in eﬀusions (P = .004, Figure 3(d)), whereas
p-ezrin levels did not signiﬁcantly diﬀer. Although the
fraction of phosphorylated protein did not signiﬁcantly
diﬀer, the total amount of the protein was up-regulated in
eﬀusions (P = .004). Thus, the absolute phosphorylated
e z r i nl e v e l sw e r eh i g h e ri ne ﬀusions compared to primary
tumors.
Immunostaining of 51 of the 52 eﬀusions (one unsatis-
factory reaction) and 27 primary carcinomas showed signif-
icantly higher p-Ezrin expression in eﬀusions compared to
primary carcinomas (P<. 001 in analysis of all cases, as well
as patient-matched specimens), as evidenced by score = 4
stainingin49/51eﬀusionsandonly2/27primarycarcinomas
(Figures 4(c)–4(e)). Ezrin was not analyzed for survival in
viewofthepracticallyuniformscore=4stainingineﬀusions.
4.4.4. Claudin-4. Immunostaining of 52 eﬀusions and 23
of the 27 primary carcinomas (4 unsatisfactory reactions)
for claudin-4 showed its presence in tumor cells in 51/52
eﬀusions and 20/23 primary carcinomas (Figures 4(f)–4(i)).
However, staining extent was higher in eﬀusions, a diﬀerence
that was signiﬁcant in analysis of all cases (P = .002), and
showed a trend in matched specimen analysis (P = .062).
Claudin-4 protein expression was unrelated to OS or DFS
(P>. 05).
4.4.5. mTOR Pathway Activity. TSC1 showed a 2.3-fold
downregulation in eﬀusions compared to primary tumors
in the array analysis. Analysis of the phosphorylation level
of the rapamycin sensitive mTOR Complex 1 (mTORC1)
substrate p70S6K showed that in spite of the TSC1 down-
regulation, the levels of p70S6K phosphorylation were lower
in eﬀusions compared to primary tumors (P = .003,
Figure 6).
5. Discussion
Breast carcinoma metastasis to the serosal cavities represents
an advanced stage in tumor progression and is associated
with extensive alterations at the molecular level, involving
clinically established targets such as HER-2 and hormone
receptors, as well as other cancer-associated molecules [7–
10]. Despite the fact that breast carcinoma is one of the
most extensively studied cancer forms, little eﬀort has been
directed towards understanding the biology of tumor cells
in malignant eﬀusions. The major aim of the present study8 Journal of Oncology
Table 2: Pathways involved in the diﬀerentially expressed genes (a): six individual eﬀusion patients against the pooled sample of primary
tumors; (b): 11 individual eﬀusions against 11 individual primary tumors.
(a)
Pathway name
Number of
genes in
pathway
Number of
diﬀerentially
expressed genes in
pathway
Percentage of
diﬀerentially
expressed genes in
pathway
P-value
Cell adhesion molecules (CAMs) 132 10 7.576 1.36E-04
Regulation of actin cytoskeleton 208 11 5.288 0.001462
Focal adhesion 195 9 4.615 0.010329
Calcium signaling pathway 175 8 4.571 0.01545
ECM-receptor interaction 87 6 6.897 0.005234
Tight junction 119 4 3.361 0.175458
PPAR signaling pathway 70 3 4.286 0.123277
TGF-beta signaling pathway 84 1 1.19 0.780451
Wnt signaling pathway 149 1 0.671 0.935266
Apoptosis 84 1 1.19 0.792465
mTOR signaling pathway 47 1 2.128 0.584796
Gap junction 92 1 1.087 0.81801
MAPK signaling pathway 256 3 1.172 0.855694
Adherens junction 77 1 1.299 0.763346
Small cell lung cancer 86 1 1.163 0.800108
Cytokine-cytokine receptor interaction 256 1 0.391 0.990004
(b)
Pathway name
Number of
genes in
pathway
Number of
diﬀerentially
expressed genes in
pathway
Percentage of
diﬀerentially
expressed genes in
pathway
P-value
Cell adhesion molecules (CAMs) 132 9 6.818 4.22E-07
Regulation of actin cytoskeleton 208 4 1.923 0.061989
Focal adhesion 195 3 1.538 0.169683
ECM-receptor interaction 87 2 2.299 0.130698
Tight junction 119 1 0.84 0.580383
TGF-beta signaling pathway 84 5 5.952 3.19E-04
Wnt signaling pathway 149 3 2.013 0.09173
Apoptosis 84 1 1.19 0.46079
mTOR signaling pathway 47 1 2.128 0.291965
MAPK signaling pathway 256 3 1.172 0.288211
Adherens junction 77 1 1.299 0.432252
Small cell lung cancer 86 4 4.651 0.003658
Cytokine-cytokine receptor interaction 256 4 1.563 0.10534
Phosphatidylinositol signaling system 77 2 2.597 0.106703
Pancreatic cancer 73 3 4.11 0.016395
Colorectal cancer 85 3 3.529 0.023709
Cell cycle 114 3 2.632 0.050093
Jak-STAT signaling pathway 153 3 1.961 0.097521
Non-small cell lung cancer 53 2 3.774 0.057405
Endometrial cancer 52 2 3.846 0.055498
B a s a lc e l lc a r c i n o m a 56 2 3.571 0.059335
Renal cell carcinoma 69 2 2.899 0.09072Journal of Oncology 9
(b) Continued.
Pathway name
Number of
genes in
pathway
Number of
diﬀerentially
expressed genes in
pathway
Percentage of
diﬀerentially
expressed genes in
pathway
P-value
Melanoma 71 2 2.817 0.09521
ErbB signaling pathway 87 2 2.299 0.133163
Melanogenesis 102 2 1.961 0.166065
Thyroid cancer 31 1 3.226 0.203583
VEGF signaling pathway 70 1 1.429 0.397797
Prostate cancer 86 1 1.163 0.468679
was to characterize a general expression ﬁngerprint that
distinguishes eﬀusions from primary tumors.
Our data show that 351 genes among 24,650 gene tran-
scripts are signiﬁcantly altered in eﬀusions in comparison
to primary carcinomas. Many of these genes are involved in
ECM-receptor interaction, focal adhesion and regulation of
the actin cytoskeleton pathways, which deﬁne the metastatic
potential of carcinoma cells by enhancing their motility and
leading to anoikis escape in the absence of ECM molecules.
PCA analysis of signiﬁcantly altered genes distinguished
clearly between primary tumors and eﬀusions. The gene
expression proﬁle correlated with phenotypic change during
the transition of breast carcinoma cells from the solid tumor
to suspended cell clusters in pleural eﬀusions. Carcinoma
cells in eﬀusions showed down-regulated ECM encoding
molecules such as decorin, ﬁbronectin, collagens I, XXII
and V, concomitantly with the downregulation of the ECM-
binding receptors, integrins α5a n dα7. Thus, it appears as if
thecellsineﬀusionslosetherequirementforinteractionwith
matrix components, possibly by a compensatory signaling
mechanism within the cells.
The second goal of the study was to highlight molecules
with multiple functional inﬂuences on the metastatic poten-
tial of cells in eﬀusions. One of these molecules is the
cytoskeleton organizer ezrin. This protein provides a func-
tional link between the plasma membrane and the actin
cytoskeleton by interacting with the cytoplasmic domains of
adhesion membrane proteins and regulation of cytoskele-
ton polymerization through the Rho pathway activation
[17]. Moreover, ezrin promotes growth and survival via
AKT/mTOR pathway activation in Ewing’s sarcoma cell lines
[18]. A recent study provided additional information regard-
ing the role of ezrin in elevation of the metastatic potential
of carcinoma cells, by showing that its downregulation of
the cell-cell adhesion molecule E-cadherin, and suggesting
that ezrin is associated indirectly with the E-cadherin/β-
catenin complex by regulating Src activation [19]. Screening
of a broad spectrum of human cancers, including breast,
lung and prostate tumors showed high expression of ezrin
in tumors of mesenchymal origin and in primary breast
carcinomas. Moreover, ezrin expression was shown to be
strongly associated with poor prognosis in breast carcinoma
[20]. In agreement with the latterreport, higher VIL2 mRNA
expression in eﬀusions was associated with poor disease-
free survival in our cohort (data not shown). This ﬁnding
requires further investigation, as it was obtained in analysis
of only 17 eﬀusions.
The up-regulation of ezrin in eﬀusions was validated
using RT-PCR, Western blotting and IHC. We found that
the up-regulation of ezrin in eﬀusions is associated with
expression of the functionally active T567 phosphorylated
ezrin [17, 18] at the plasma membrane. This gene is not
only up-regulated at the mRNA and protein levels, but is
also more active in eﬀusions compared to solid tumors.
Since the increase in ezrin activation may inﬂuence multiple
metastasis-associated cell functions [17, 18], the therapeutic
targeting of this protein may prove beneﬁcial in eﬀusion
therapy.
Statistical analysis of the array results showed that
the TSC1 gene, encoding a protein involved in mTORC1
inhibition, is down-regulated in eﬀusions in comparison
to primary tumors. The mTOR pathway is highly involved
in breast carcinoma pathogenesis and adjuvant therapy
resistance [21]. Moreover, there is evidence that mTOR
activation can lead to anchorage-independent growth of
carcinomacells[22],makingitapotentiallyimportantfactor
for cell survival in eﬀusions. Rapamycin analogues, such
as temsirolimus (CCI-779) or everolimus (RAD-001) that
target mTOR are now in diﬀerent stages of clinical trials
for anti-cancer therapy as a single agent [23] or as additive
treatment having synergetic eﬀect with ER- and HER2/neu-
targeted therapy [24, 25]. Downregulation of the mTOR
inhibitor TSC1 in eﬀusion may lead to subsequent activation
of mTORC1 at this site of metastasis, suggesting that this
signaling pathway may be altered along tumor progression
in breast carcinoma.
Recent studies demonstrate that TSC1 directly interacts
with ezrin and through this interaction regulates focal adhe-
sion complex formation and causes cytoskeletal remodeling
[26, 27] .T h el o s so fTCS1 results in loss of focal adhesions,
cell rounding and progressive detachment of cells from the
substrate [27]. Since eﬀusions are characterized as clusters of
detached carcinoma cells, the parallel dysregulation of TSC1
and ezrin expression may play a critical role in eﬀusion for-
mation. The relative phosphorylation extent of the mTORC1
substrate p70S6K [28, 29] was measured in order to analyze
the eﬀect of TSC1 downregulation on the mTORC1 activity.
In spite of the downregulation of the mTORC1 inhibitor
TSC1, the extent of p70S6K phosphorylation remains low in
the eﬀusions in comparison to primary tumors. The reason10 Journal of Oncology
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Figure 3: Validation by PCR and Western blotting.( a ) :DCN mRNA expression in eﬀusions and solid primary tumors, showing higher
expression in the latter specimen type (P<. 0001). DCN levels were measured by qRT-PCR using speciﬁc primers for decorin A1, A2
and B isoformes. The pool sample consisting of cDNA from ﬁve primary tumors and ﬁve eﬀusion samples served as a positive control. DCN
mRNAexpressionlevelswerenormalizedtoRPLPOreferencegeneexpressionlevels.(b):BCAR1mRNArelativeexpressionlevelsinprimary
tumorsandeﬀusions.GeneexpressionlevelwasmeasuredbysemiquantitativeRT-PCRandnormalizedtorelative28sexpression.TheMCF-
7 breast carcinoma cell line served as positive control. BCAR1 levels were signiﬁcantly higher in eﬀusions (P<. 0001). (c): VIL2 expression
in eﬀusions in comparison to primary carcinomas. VIL2 mRNA levels were measured by RT-PCR with speciﬁc primers and normalized to
relative 28s expression. Human HT1080 ﬁbrosarcoma cell line served as a positive control. VIL2 levels were signiﬁcantly higher in eﬀusions
(P<. 0001). (d): Total Ezrin protein expression in eﬀusions in comparison to primary carcinomas. Ezrin protein levels were analyzed using
speciﬁc antibodies and normalized to total beta-actin levels. Ezrin levels were signiﬁcantly higher in eﬀusions (P = .004).
for low mTORC1 activity in eﬀusions should be investigated.
One possible explanation is that other substrates of mTOR
may be relevant and p70S6K may be a minor eﬀector of this
pathway in eﬀusions.
Hormone receptor status and the relevance of adjuvant
hormonaltherapyatdiﬀerentstagesofthediseasearecentral
in breast carcinoma research [30]. We have previously shown
that ER is down-regulated in eﬀusions in comparison to
primarytumors[8].InthepresentstudyweobservedBCAR1
gene up-regulation in eﬀusions. High BCAR1 expression was
reported to be associated with a poor response to ﬁrst-line
tamoxifentherapyinpatientswithrecurrentdiseaseandwith
an increased rate of relapse [31]. Moreover, overexpression
of BCAR1 causes tamoxifen resistance in tamoxifen-sensitive
breast carcinoma cells [32]. The up-regulation of p130cas
in eﬀusions can be a result of population enrichment byJournal of Oncology 11
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4: Validation by immunohistochemistry. (a)-(b), p130cas: Immunostaining for p130cas in a primary carcinoma (a) and pleural
eﬀusion (b) showing cytoplasmic staining in tumor cells. (c)–(f), p-Ezrin: Immunostaining for p-Ezrin in a primary carcinoma (c), pleural
eﬀusion from the same patient (d), and 2 additional eﬀusions obtained from the pericardial (e) and pleural (f) cavity. Tumor cells in the
primarycarcinomaarep-Ezrin-negative,whereascellsinallthreeeﬀusionsarestainedatthemembrane.(g)–(i),claudin-4:immunostaining
for Claudin-4 in a primary carcinoma (g), pleural eﬀusion from the same patient (h), and an additional eﬀusion obtained from the
pericardial cavity (i,samespecimen as ine). Tumorcells intheprimarycarcinoma areClaudin-4-negative, whereas cells inthe twoeﬀusions
are stained at the membrane.
resistant cells due to tamoxifen treatment. Thus, BCAR1
expression status in eﬀusions must be taken under consid-
eration while choosing therapeutic regimen in patients with
breast carcinoma eﬀusions. On the other hand, p130cas is
ad o w n s t r e a me ﬀector of integrins [33]. The up-regulation
of p130cas can lead to subsequent activation of Rac pathway
and actin cytoskeleton rearrangements [34, 35]. This can
elevate the metastatic potential of the cells in eﬀusions by
enhancing cell migration and leading to anoikis escape, as
has been shown in in vitro systems [36, 37].
In contrast to the established importance of ER-α
as a breast cancer marker, the prognostic and predictive
relevance of ER-β remains unclear. Several previous reports
have shown correlation between low ER-β expression and
advanced disease stage and shorter survival in various
tumors, including gynecological carcinomas [38–40]. In the
present study we found downregulation of ER-β in eﬀusions.
Since breast carcinoma eﬀusions constitute stage IV disease,
this observation is concordant with the above-detailed
publications. Low ER-β levels in eﬀusions may contribute
to tamoxifen resistance, as had been shown in ER-positive
primary breast carcinomas [41]. Thus, the expression levels
of ER-β may inﬂuence decisions regarding therapeutic
regimens for patients with this form of metastatic disease.
Claudins are a family of tight junction (TJ)-speciﬁc
integral membrane proteins, including more than 20 mem-
bers to date. TJs, located between epithelial or endothelial
cells, at the apical region of the adjacent lateral membranes,12 Journal of Oncology
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Figure 5: The prognostic role of p130cas expression in breast carcinoma eﬀusions. (a): Kaplan-Meier survival curve showing the trend for
association between p130cas expression and overall survival (OS) for 44 patients with breast carcinoma eﬀusions. Patients with eﬀusions
with higher expression (>25% of tumor cells) (n = 33, dashed line) had a mean OS of 78 months versus 142 months for patients whose
eﬀusions showed low (≤25%) expression (n = 11, solid line; P = .062). (b): Kaplan-Meier survival curve showing the trend for association
between p130cas expression and disease-free survival (DFS) for 42 patients with breast carcinoma eﬀusions. Patients with eﬀusions with
higher expression (>2 5 %o ft u m o rc e l l s )( n = 31, dashed line) had a mean DFS of 48 months versus 89 months for patients whose eﬀusions
showed low (≤25%) expression (n = 11, solid line; P = .098). DFS data were unavailable for 2 patients.
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Figure 6: Reduced p70S6K phosphorylation in breast carcinoma
eﬀusions compared to primary tumors. mTOR activity measured
by Western blot analysis of the mTORC1 substrate p70S6K
phosphorylation extent in eﬀusions (n = 16) and primary tumors
(n = 22). Phosphorylated p70-S6K protein levels were analyzed
using phospho-speciﬁc antibodies and normalized to total p70S6K
levels. The 3T3-NIH cell line served as a positive control.
control the paracellular transport of solutes and maintain
cell polarity by blocking the free diﬀusion of proteins
and lipids between the apical and basolateral domains of
the plasma membrane [42–44]. TJ ﬁlaments also contain
occludin, the ﬁrst TJ-speciﬁc integral membrane protein
identiﬁed, yet it has been shown that claudins are essential
and suﬃcient to form TJ strands [45]. The structure of
claudins consists of intracellular amino and carboxy termini,
four transmembrane domains, and two extracellular loops
mediating interactions between claudins on adjacent cells
[42–44]. The second extracellular loop serves as a binding
site for Clostridium perfringens enterotoxin in claudin-3 and
-4 [45]. The carboxy terminus of most claudins contains
potential serine and/or thereonine phosphorylation sites
and a PDZ-binding motif, to which the TJ cytoplasmic
scaﬀolding proteins ZO-1, -2 and -3 bind [44].
We have recently shown that several claudin family
members are upregulated in ovarian carcinoma eﬀusions
compared to corresponding primary carcinomas [46]. In
the present study, we found upregulation of claudin-4 in
breast carcinoma eﬀusions compared to primary carcino-
mas, suggesting that members of this family are upregulated
at this anatomic site in multiple epithelial malignancies. Our
observations are in agreement with a recent study in which
claudin-4 expression was shown to be associated with high
grade and poor prognosis in breast carcinoma [46]. The
previously discovered role of claudin-3 and claudin-4 in cell
motilityandincreasedMMP-2activity[47]suggeststhatthis
may be yet another metastasis-promoting molecule in breast
carcinoma eﬀusions.
In conclusion, gene array analysis of breast carcinoma
eﬀusions and primary carcinomas showed diﬀerences in
expression of multiple genes regulating cell motility, inva-
sion and metastasis. The study of eﬀusions and the way
they diﬀer from solid tumors will expand our knowledge
regarding tumor progression in general, as well as regarding
malignancies aﬀecting this anatomic site in particular, and
may have an impact on treatment modalities and prognostic
models.Journal of Oncology 13
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